| Paller, Amy |
NCT05042258: Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis |
|
|
| Recruiting | 4 | 40 | US | Dupilumab, Dupixent | Northwestern University, Regeneron Pharmaceuticals | Atopic Dermatitis, Sleep Disturbance | 06/25 | 12/25 | | |
VAPAUS, NCT05180708: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita |
|
|
| Completed | 3 | 87 | Europe, US | QTORIN 3.9% rapamycin anhydrous gel, Vehicle | Palvella Therapeutics, Inc. | Pachyonychia Congenita | 06/23 | 06/23 | | |
NCT04917874: A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa |
|
|
| Completed | 3 | 47 | US | Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech, Inc. | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | 07/23 | 07/23 | | |
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS) | Eli Lilly and Company, Dermira, Inc. | Atopic Dermatitis, Eczema | 02/26 | 02/27 | | |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis |
|
|
| Enrolling by invitation | 3 | 310 | Europe, Canada, Japan, US, RoW | Lebrikizumab, LY3650150, Placebo | Eli Lilly and Company | Atopic Dermatitis, Eczema | 06/26 | 06/26 | | |
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) |
|
|
| Recruiting | 2/3 | 80 | Europe, US, RoW | AC-203, Vehicle | TWi Biotechnology, Inc. | Generalized Epidermolysis Bullosa Simplex | 08/25 | 03/26 | | |
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) |
|
|
| Not yet recruiting | 2 | 86 | US | ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel | National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc. | Atopic Dermatitis | 06/26 | 07/26 | | |
NCT05866562: Dupilumab in the Treatment of Pediatric Alopecia Areata |
|
|
| Recruiting | 2 | 76 | US | Dupilumab, Dupixent, Placebo | Icahn School of Medicine at Mount Sinai | Alopecia Areata | 05/28 | 05/29 | | |
NCT06545695: Epidermal Growth Factor Receptor Inhibition for Keratinopathies |
|
|
| Not yet recruiting | 1/2 | 44 | US | Erlotinib | Northwestern University, Yale University | Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia Congenita | 06/29 | 06/29 | | |
NCT05533866: Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution |
|
|
| Active, not recruiting | 1 | 16 | US | APR-TD011, Nexodyn AOS | Northwestern University | Epidermolysis Bullosa | 09/24 | 02/25 | | |
NCT04549792: An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses |
|
|
| Completed | 1 | 13 | US | Ustekinumab | Northwestern University, Janssen Scientific Affairs, LLC | Ichthyosis | 01/24 | 06/24 | | |
NCT05649098: Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders |
|
|
| Recruiting | 1 | 30 | US | Dupilumab | Northwestern University | Skin Diseases | 06/25 | 06/26 | | |
NCT04486742: Brief Cognitive Behavioral Therapy to Treat Itch Rumination "Itch CBT" in Eczema |
|
|
| Completed | N/A | 20 | US | Itch CBT | Northwestern University, Ann & Robert H Lurie Children's Hospital of Chicago | Atopic Dermatitis | 12/21 | 12/21 | | |
NCT01782703: Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis |
|
|
| Recruiting | N/A | 930 | US | | Northwestern University, Rockefeller University, Icahn School of Medicine at Mount Sinai | Atopic Dermatitis, Eczema | 12/25 | 12/25 | | |
NCT03417856: Defining the Skin and Blood Biomarkers of Ichthyosis |
|
|
| Recruiting | N/A | 200 | US | | Northwestern University, Icahn School of Medicine at Mount Sinai, Galderma R&D | Ichthyosis, Netherton Syndrome | 12/25 | 12/25 | | |
NCT05843994: Artificial Intelligence Patient App for RDEB SCCs |
|
|
| Active, not recruiting | N/A | 20 | US | online survey | Northwestern University, Epidermolysis Bullosa Research Partnership | Epidermolysis Bullosa Dystrophica | 11/23 | 11/25 | | |
NCT03791216: Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment |
|
|
| Active, not recruiting | N/A | 62 | US | Fasting blood draw for lipid assessments | Northwestern University, National Psoriasis Foundation, National Heart, Lung, and Blood Institute (NHLBI), Children's Hospital of Philadelphia, Radboud University Medical Center | Psoriasis | 02/25 | 06/25 | | |
| Recruiting | N/A | 50 | US | wool clothing, standard clothing | Murdoch Childrens Research Institute, Australian Wool Innovation Ltd, Northwestern University, United Christian Hospital | Dermatitis, Atopic | 10/24 | 10/24 | | |
| Recruiting | N/A | 2500 | US | | National Institute of Allergy and Infectious Diseases (NIAID), Consortium for Food Allergy Research, Rho Federal Systems Division, Inc. | Allergic Diseases, Food Allergy, Atopic Dermatitis | 09/28 | 09/28 | | |
NCT02418442: Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry |
|
|
| Recruiting | N/A | 20000 | Europe, Canada, US, RoW | | Duke University, Childhood Arthritis and Rheumatology Research Alliance | Rheumatic Joint Disease | 06/28 | 12/28 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Leung, Donald |
LEADS, NCT05436535: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis |
|
|
| Recruiting | 4 | 600 | US | Dupilumab, Dupixent, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab | National Institute of Allergy and Infectious Diseases (NIAID) | Atopic Dermatitis | 05/25 | 10/25 | | |
OUtMATCH, NCT03881696: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants |
|
|
| Active, not recruiting | 3 | 471 | US | Omalizumab, Xolair®, Placebo for Omalizumab, Placebo, Multi-Allergen Oral Immunotherapy, Multi-Allergen OIT, Placebo for Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen OIT, Double-Blind Placebo-Controlled Food Challenge Based Treatment, DBPCFC Based Treatment | National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Inc., Novartis Pharmaceuticals, Rho Federal Systems Division, Inc. | Peanut Allergy, Multi-food Allergy | 03/23 | 06/25 | | |
|
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) |
|
|
| Not yet recruiting | 2 | 86 | US | ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel | National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc. | Atopic Dermatitis | 06/26 | 07/26 | | |
| Recruiting | 2 | 312 | Europe, US | Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care | Kari Nadeau, MD, PhD, King's College London and Guy's & St. Thomas Hospital, National Jewish Health, University of Chicago, Children's Hospital Medical Center, Cincinnati, Harvard School of Public Health (HSPH), Stanford University | Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis | 05/27 | 06/27 | | |
NCT04060550: Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum |
|
|
| Recruiting | N/A | 36 | US | Xolair, omalizumab | National Jewish Health, Genentech, Inc. | Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum, Health Controls Without Atopy | 07/21 | 07/21 | | |
NCT04445298: Skin Barrier Assessment in Pregnancy and at Birth |
|
|
| Recruiting | N/A | 160 | US | Transepidermal water loss, TEWL, Skin tape stripping, STS, Blood draw, Bacterial PCR swab, PCR | National Jewish Health | Pregnancy Related, Allergy, Atopic Dermatitis Eczema, Asthma in Children, Food Allergy | 07/22 | 07/22 | | |
NCT02910791: The Role of Bacterial Toxins in Human Skin Disease |
|
|
| Recruiting | N/A | 100 | US | | National Jewish Health | Atopic Dermatitis, Psoriasis | 12/22 | 12/23 | | |
| Recruiting | N/A | 2500 | US | | National Institute of Allergy and Infectious Diseases (NIAID), Consortium for Food Allergy Research, Rho Federal Systems Division, Inc. | Allergic Diseases, Food Allergy, Atopic Dermatitis | 09/28 | 09/28 | | |
| Beck, Lisa |
LEADS, NCT05436535: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis |
|
|
| Recruiting | 4 | 600 | US | Dupilumab, Dupixent, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab | National Institute of Allergy and Infectious Diseases (NIAID) | Atopic Dermatitis | 05/25 | 10/25 | | |
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) |
|
|
| Not yet recruiting | 2 | 86 | US | ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel | National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc. | Atopic Dermatitis | 06/26 | 07/26 | | |
| Recruiting | 2 | 68 | US | Dupilumab, Placebo | Emma Guttman, Regeneron Pharmaceuticals | Alopecia Areata | 12/26 | 12/27 | | |
| Recruiting | N/A | 240 | US | AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures | University of Rochester | Atopic Dermatitis, Psoriasis | 04/26 | 04/26 | | |
| Smith, Michelle D |
LEADS, NCT05436535: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis |
|
|
| Recruiting | 4 | 600 | US | Dupilumab, Dupixent, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab | National Institute of Allergy and Infectious Diseases (NIAID) | Atopic Dermatitis | 05/25 | 10/25 | | |
SUGARNSALT, NCT06217302: Sotagliflozin to Slow Kidney Function Decline in Persons with Type 1 Diabetes and Diabetic Kidney Disease |
|
|
| Recruiting | 3 | 150 | Canada, US | Sotagliflozin, INPEFA, Placebo | Alessandro Doria, Canadian Institutes of Health Research (CIHR), The Kidney Foundation of Canada, The Cleveland Clinic, University of Michigan, University of Colorado, Denver, Northwestern University, Washington University School of Medicine, State University of New York - Upstate Medical University, Providence Medical Research Center, Stanford University, Montefiore Medical Center, University of Toronto, University Health Network, Toronto, University of Calgary, University of Alberta, University of British Columbia, Institut de Recherches Cliniques de Montreal, LMC Diabetes & Endocrinology Ltd., Joslin Diabetes Center, Lexicon Pharmaceuticals, DexCom, Inc., University of Washington, Breakthrough T1D | Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure | 12/28 | 05/29 | | |
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) |
|
|
| Not yet recruiting | 2 | 86 | US | ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel | National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc. | Atopic Dermatitis | 06/26 | 07/26 | | |
| Withdrawn | N/A | 30 | NA | Philips Respironics V60 Non-invasive ventilator, BPAP, Philips Respironics V60 Non-invasive ventilator, Standard Therapy | Columbia University | Asthma in Children, Status Asthmaticus | 07/22 | 07/22 | | |
